FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2589855317> ?p ?o ?g. }

• W2589855317 abstract "1038 Background: Metaplastic breast carcinoma (MBC) is a rare subtype that accounts for <1% of all breast carcinomas. MBC is frequently triple negative and neoadjuvant chemotherapy (NAC) is often used in triple negative breast cancer (TNBC). The objective of this analysis is to ascertain response rates of MBC to NAC as compared to non-metaplastic TNBC. Methods: We searched the Magee Women’s Cancer Center of UPMC IRB-approved neo-adjuvant treatment database which contains outcome data on 594 patients treated from 2004-2010. 116 patients with triple negative breast cancer (ER /PR negative or ER /PR weakly positive (H score of 10 or less) and HER2 negative or indeterminate (HER2 1+ or 2+ without amplification by FISH)), were identified. Nine of these TNBCs had metaplastic subtype and 2 groups were analyzed: metaplastic breast carcinoma (MBC) (N= 9) and non-metaplastic breast carcinoma (NMBC) (N = 107). Tumor volume reduction (TVR), pathologic complete response (pCR), recurrence and mortality were compared in both groups. Results: Mean follow up in MBC group was 43 months and no patients were lost to follow up. Mean tumor size on presentation in MBC group was 4.47 cm while in NMBC group it was 3.33 cm. pCR was noted in 0/9 MBC and 43/107 NMBC cases (p = 0.0253). 6/9 patients had mastectomy, 2/9 had breast conserving surgery (BCS) and 1/9 patients did not have a surgery yet. Average TVR was 28% in MBC cases compared to 74% in NMBCs when cases with pCR were included (p = 0.0001) and 56% when cases with pCR were excluded (p = 0.0202). Follow up on 9 MBC cases revealed 1 recurrence and subsequent death (11%). Follow up on 64 NMBC patients who failed to achieve pCR revealed 22 recurrences (34%) and 18 of them subsequently died (28%).Follow up on 43 NMBC cases that achieved pCR revealed 3 recurrences (7%) and 1 death (2%). Conclusions: MBC was characterized by larger size at baseline as compared to NMBC. There were no pCR’s seen in MBC, but some MBC did achieve response that allowed for breast conservation. Although the average tumor volume reduction was significantly less in MBC compared to NMBC, the NMBC that failed to achieve pCR fared much worse than MBC who did not achieve pCR. Therefore, the triple negative paradox is likely not applicable to MBC." @default.
• W2589855317 created "2017-03-03" @default.
• W2589855317 creator A5024527435 @default.
• W2589855317 creator A5034149172 @default.
• W2589855317 creator A5034478840 @default.
• W2589855317 creator A5035399830 @default.
• W2589855317 date "2012-05-20" @default.
• W2589855317 modified "2023-09-24" @default.
• W2589855317 title "Single institution experience with neoadjuvant chemotherapy for metaplastic breast cancer (MBC)." @default.
• W2589855317 doi "https://doi.org/10.1200/jco.2012.30.15_suppl.1038" @default.
• W2589855317 hasPublicationYear "2012" @default.
• W2589855317 type Work @default.
• W2589855317 sameAs 2589855317 @default.
• W2589855317 citedByCount "1" @default.
• W2589855317 countsByYear W25898553172020 @default.
• W2589855317 crossrefType "journal-article" @default.
• W2589855317 hasAuthorship W2589855317A5024527435 @default.
• W2589855317 hasAuthorship W2589855317A5034149172 @default.
• W2589855317 hasAuthorship W2589855317A5034478840 @default.
• W2589855317 hasAuthorship W2589855317A5035399830 @default.
• W2589855317 hasConcept C121608353 @default.
• W2589855317 hasConcept C126322002 @default.
• W2589855317 hasConcept C143998085 @default.
• W2589855317 hasConcept C2776047466 @default.
• W2589855317 hasConcept C2776694085 @default.
• W2589855317 hasConcept C2778292576 @default.
• W2589855317 hasConcept C2780110267 @default.
• W2589855317 hasConcept C3018521938 @default.
• W2589855317 hasConcept C530470458 @default.
• W2589855317 hasConcept C71924100 @default.
• W2589855317 hasConceptScore W2589855317C121608353 @default.
• W2589855317 hasConceptScore W2589855317C126322002 @default.
• W2589855317 hasConceptScore W2589855317C143998085 @default.
• W2589855317 hasConceptScore W2589855317C2776047466 @default.
• W2589855317 hasConceptScore W2589855317C2776694085 @default.
• W2589855317 hasConceptScore W2589855317C2778292576 @default.
• W2589855317 hasConceptScore W2589855317C2780110267 @default.
• W2589855317 hasConceptScore W2589855317C3018521938 @default.
• W2589855317 hasConceptScore W2589855317C530470458 @default.
• W2589855317 hasConceptScore W2589855317C71924100 @default.
• W2589855317 hasLocation W25898553171 @default.
• W2589855317 hasOpenAccess W2589855317 @default.
• W2589855317 hasPrimaryLocation W25898553171 @default.
• W2589855317 hasRelatedWork W1970419458 @default.
• W2589855317 hasRelatedWork W1997730866 @default.
• W2589855317 hasRelatedWork W2017664331 @default.
• W2589855317 hasRelatedWork W2075286053 @default.
• W2589855317 hasRelatedWork W2127543027 @default.
• W2589855317 hasRelatedWork W2245723046 @default.
• W2589855317 hasRelatedWork W2290064931 @default.
• W2589855317 hasRelatedWork W2356067873 @default.
• W2589855317 hasRelatedWork W2376078656 @default.
• W2589855317 hasRelatedWork W2398282639 @default.
• W2589855317 hasRelatedWork W2425050493 @default.
• W2589855317 hasRelatedWork W2609874944 @default.
• W2589855317 hasRelatedWork W2623258196 @default.
• W2589855317 hasRelatedWork W2625408312 @default.
• W2589855317 hasRelatedWork W2767141639 @default.
• W2589855317 hasRelatedWork W2783881873 @default.
• W2589855317 hasRelatedWork W3005028195 @default.
• W2589855317 hasRelatedWork W3092457987 @default.
• W2589855317 hasRelatedWork W3190343290 @default.
• W2589855317 hasRelatedWork W99781629 @default.
• W2589855317 isParatext "false" @default.
• W2589855317 isRetracted "false" @default.
• W2589855317 magId "2589855317" @default.
• W2589855317 workType "article" @default.